FundedIQ
Biotechnology

Mirxes: Funding, Investors & Team (Sep 2026)

Mirxes is a biotech firm focused on uncovering, advancing, and providing precise preventive healthcare remedies for cancer, heart-related issues, metabolic disorders, and infectious diseases. The primary objective of the company is to make diagnostic solutions that can identify diseases at an early stage globally accessible. It produces and markets highly accurate blood-based miRNA test kits for the prompt identification of cancer and various other ailments, while ensuring a non-invasive approach.

www.mirxes.com LinkedIn Singapore, Singapore 251-500 employees
Total raised
$177M
Rounds
3
Latest
Undisclosed round
Jan 2025

Mirxes has raised $177M across 3 funding rounds on record, the most recent an undisclosed round of $40.0M announced in Jan 2025.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Mirxes Company Profile and Key Stats

Total funding raised
$177M
across 3 rounds on record
Funding rounds on record
3
Latest funding round
Undisclosed round
$40.0M in Jan 2025
Employees
251-500
reported band
Headquarters
Singapore, Singapore

Latest funding round on record: Jan 2025.

Mirxes Funding Rounds

Date
Round
Amount
Undisclosed round
$40.0M
Series D
$50.0M
Series C
$87.0M

Mirxes raised $87.0M in a Series C announced in Feb 2022.

1.4 years later, a Series D of $50.0M was announced in Jul 2023.

1.5 years later, an undisclosed round of $40.0M was announced in Jan 2025.

Mirxes Founders and Leadership Team

Name
Role
Contact
Zou Ruiyang
Founder
LiHan Zhou
CEO

No contact details are on record for this team yet.

Mirxes Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
985
$5.0M

Mirxes' latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Mirxes in Biotechnology and Singapore

Companies Similar to Mirxes

YouLabs is an early-stage, data-driven biotechnology and longevity technology company focused on shifting…

Seed $2.6M

Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based…

Undisclosed round $4.6M

ImmunoScape is a company focused on immunomics, using a technology platform to analyze and characterize the…

Undisclosed round

Nuevocor, which has locations in both the United States and Singapore, is working on creating genetic…

Series B $45.0M

Aevice Health Pte Ltd is a Singaporean company that originated from Nanyang Technological University and…

Undisclosed round

BioDefense introduces Bioshield, a product derived from edible ingredients designed to safeguard your food by…

Pre-Seed $100k

Auristone delivers practical clinical insights through our epigenomics workflows, providing actionable…

Seed $4.0M

ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in…

Undisclosed round $5.0M

GDMC is a pharmaceutical organization that specializes in the production and development of genetic…

Series A $21.0M

Meatiply, a company focused on food research, specializes in the creation and manufacturing of meat…

Seed $3.8M

Empowering Healthier Meals by Harnessing the Best from Nature and Combining that our Knowledge of Food…

Undisclosed round $6.0M

Automera dedicates itself to the creation of innovative therapeutic approaches for drug development.

Series A $16.0M

Mirxes Funding FAQs

What does Mirxes do?

Mirxes is a biotech firm focused on uncovering, advancing, and providing precise preventive healthcare remedies for cancer, heart-related issues, metabolic disorders, and infectious diseases. The primary objective of the company is to make diagnostic solutions that can identify diseases at an early stage globally accessible. It produces and markets highly accurate blood-based miRNA test kits for the prompt identification of cancer and various other ailments, while ensuring a non-invasive approach.

How much funding has Mirxes raised?

Mirxes has raised $177M across 3 rounds on record. The most recent is an undisclosed round of $40.0M announced in Jan 2025.

When did Mirxes last raise funding?

Mirxes' most recent funding round on record is an undisclosed round of $40.0M, announced in Jan 2025.

Who founded Mirxes?

FundedIQ lists Zou Ruiyang (Founder) at Mirxes.

Who is the CEO of Mirxes?

LiHan Zhou is listed as CEO at Mirxes.

Where is Mirxes headquartered?

Mirxes is based in Singapore, Central Region, Singapore.

How many employees does Mirxes have?

Mirxes is in the 251-500 employee band.

How does Mirxes' funding compare to other Biotechnology startups?

Mirxes' latest round of $40.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's Mirxes Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mirxes is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.